How much does ruxolitinib tablets/ruxolitinib cost after being included in medical insurance?

Ruxolitinib is a targeted cancer drug that can be used to treat certain myeloproliferative tumors, such as: myelofibrosis, polycythemia vera, and can also be used to graft versus host disease (GVHD). Ruxolitinib is also known asJakavi.

As a targeted cancer drug, ruxolitinib is also called a cancer growth inhibitor. Cancer growth blockers block growth factors that trigger cancer cells to divide and grow. Ruxolitinib works by blocking a gene important in the production of blood cells. This gene is called Janus-associated kinase 1 or 2 (JAK 1 or JAK2). Before starting treatment, patients will need a blood test to check for changes in the JAK gene. Patients take ruxolitinib tablets, usually twice a day, which can be taken at the same time each day. Tell your doctor if you miss a dose or want to stop taking your cancer medicine. You can continue taking ruxolitinib tablets as long as the treatment is effective and you do not experience too many side effects.

The original drug ruxolitinib tablets have been launched in China, and have also been included in the scope of Class B medical insurance reimbursement through the relevant regulations of the National Medical Insurance Administration. Patients who meet the indications can enjoy medical insurance reimbursement when purchasing this drug in hospitals or pharmacies. The current domestically marketed drug specifications are 20mg*14 tablets and 5mg*60 tablets. The price of each box may be around 3,000 yuan, and the price will be reduced after medical insurance reimbursement. However, due to different reimbursement ratios in different regions, there may be slight differences in the price after reimbursement. Relevant information about drug medical insurance reimbursement can be obtained from the local medical insurance bureau or hospital.